Sandrine Audouy
University of Groningen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sandrine Audouy.
Pharmaceutical Research | 2002
Sandrine Audouy; Lou de Leij; Dick Hoekstra; Grietje Molema
After a decade of clinical trials, gene therapy seems to have found its place between excessive ambitions and feasible aims, with encouraging results obtained in recent years. Intracellular delivery of genetic material is the key step in gene therapy. Optimization of delivery vectors is of major importance for turning gene therapy into a successful therapeutic method. Nonviral gene delivery relies mainly on the complexes formed from cationic liposomes (or cationic polymers) and DNA, i.e., lipoplexes (or polyplexes). Many lipoplex formulations have been studied, but in vivo activity is generally low compared to that of viral systems. This review gives a concise overview of studies on the application of cationic liposomes in vivo in animal models of diseases and in clinical studies. The transfection efficiency, the pharmacokinetic and pharmacodynamic properties of the lipid-DNA complexes, and potentially relevant applications for cationic liposomes are discussed. Furthermore, the toxicity of, and the induction of an inflammatory response in association with the administration of lipoplexes are described. Increasing understanding of lipoplex behavior and gene transfer capacities in vivo offers new possibilities to enhance their efficiency and paves the path to more extensive clinical applications in the future.
Applied and Environmental Microbiology | 2006
Tjibbe Bosma; Rolf Kanninga; Jolanda Neef; Sandrine Audouy; Maarten L. van Roosmalen; Anton Steen; Girbe Buist; Jan Kok; Oscar P. Kuipers; George T. Robillard; Kees Leenhouts
ABSTRACT A novel display system is described that allows highly efficient immobilization of heterologous proteins on bacterial surfaces in applications for which the use of genetically modified bacteria is less desirable. This system is based on nonliving and non-genetically modified gram-positive bacterial cells, designated gram-positive enhancer matrix (GEM) particles, which are used as substrates to bind externally added heterologous proteins by means of a high-affinity binding domain. This binding domain, the protein anchor (PA), was derived from the Lactococcus lactis peptidoglycan hydrolase AcmA. GEM particles were typically prepared from the innocuous bacterium L. lactis, and various parameters for the optimal preparation of GEM particles and binding of PA fusion proteins were determined. The versatility and flexibility of the display and delivery technology were demonstrated by investigating enzyme immobilization and nasal vaccine applications.
Journal of Gene Medicine | 2000
Sandrine Audouy; Grietje Molema; Lou de Leij; Dick Hoekstra
Cationic liposomes belong to the family of non‐viral vectors for gene delivery. Despite several drawbacks, such as low efficiency compared to viruses and inactivation by serum, cationic liposomes remain a promising tool for gene therapy. Therefore further investigation of the mechanism of transfection and improvement of formulations are warranted.
Molecular Membrane Biology | 2001
Sandrine Audouy; Dick Hoekstra
Recent rapid developments in genomics will likely lead to a rapid expansion in identifying defective genes causing a variety of diseases, implying a vast increase in the number of therapeutic targets. Treatment of such diseases may include strategies ranging from gene delivery and replacement to antisense approaches. For successful development of gene therapies, a minimal requirement involves the engineering of appropriate gene- or oligonucleotide-carrier systems, which are necessary for protective purposes (against nucleases) and transport (to target tissue and cells in vivo). Further, they should also display the propensity to efficiently translocate the oligonucleotides and gene constructs into cells, via passage across several membrane barriers. The emphasis in this review will be on the use of cationic lipids for that purpose. Crucial to successful application of this sophisticated technology in vivo will be a need for a better understanding of fundamental and structural parameters that govern transfection efficiency, including the issues of cationic lipid/DNA complex assembly (with or without helper lipid), stability towards biological fluids, complex-target membrane interaction and translocation, and gene-integration into the nucleus. Biophysical and biochemical characterization of so called lipoplexes, and their interaction with cells in vitro, are considered instrumental in reaching such insight. Here, most recent advances in cationic lipid-mediated gene delivery are discussed from such a perspective.
Cancer Gene Therapy | 2004
J. van Zanten; B Doornbos-van Meer; Sandrine Audouy; Robbert J. Kok; Lou de Leij
In this study, we developed a nonviral, cationic, targeted DNA–carrier system by coupling SAINT/DOPE lipids to monoclonal antibodies. The two monoclonal antibodies used were both tumor specific, that is, MOC31 recognizes the epithelial glycoprotein EGP-2 present in carcinomas and Herceptin recognizes the HER-2/neu protein in breast and ovarian cancers. Coupling was performed under nonreducing conditions by covalent attachment. The coupling procedure appeared to be reproducible and the binding capacity of the antibody was not affected by linking them to the cationic lipid. Binding and transfection efficiency was assayed with target cells and nontarget cells. SAINT/DOPE lipoplexes as such appeared to be an effective transfection reagent for various cell lines. After coupling SAINT/DOPE to the monoclonal antibodies or F(ab)2 fragments, it was shown that the targeted MoAb-SAINT/DOPE lipoplexes preferably bound to target cells, compared to binding to the nontarget cells, especially for the Herceptin-SAINT/DOPE lipoplexes. More importantly, transfection of the target cells could also be improved with these targeted lipoplexes. In conclusion, we have shown that by using monoclonal antibody-coupled SAINT/DOPE lipoplexes cells targeted gene delivery can be achieved, and also a higher number of transfected target cells was seen.
Malaria Journal | 2012
Krystelle Nganou-Makamdop; Maarten L. van Roosmalen; Sandrine Audouy; Geert-Jan van Gemert; Kees Leenhouts; Cornelus C. Hermsen; Robert W. Sauerwein
BackgroundVirus-like particles have been regularly used as an antigen delivery system for a number of Plasmodium peptides or proteins. The present study reports the immunogenicity and protective efficacy of bacterium-like particles (BLPs) generated from Lactococcus lactis and loaded with Plasmodium berghei circumsporozoite protein (PbCSP) peptides.MethodsA panel of BLP-PbCSP formulations differing in composition and quantity of B-cell, CD4+ and CD8+ T-cell epitopes of PbCSP were tested in BALB/c mice.ResultsBLP-PbCSP1 induced specific humoral responses but no IFN-γ ELISPOT response, protecting 30-40% of the immunized mice. BLP-PbCSP2, with reduced length of the non-immunogenic part of the T-cell-epitopes construct, increased induction of IFN-γ responses as well as protection up to 60-70%. Compared to controls, lower parasitaemia was observed in unprotected mice immunized with BLP-PbCSP1 or 2, suggestive for partial immunity. Finally, further increase of the number of B-cell epitopes and codon optimization (BLP-PbCSP4) induced the highest anti-CSP antibody levels and number of IFN-γ spots, resulting in sterile immunity in 100% of the immunized mice.ConclusionPresentation of Plasmodium-derived antigens using BLPs as a delivery system induced complete protection in a murine malaria model. Eventually, BLPs have the potential to be used as a novel versatile delivery platform in malaria vaccine development.
Methods | 2006
Maarten L. van Roosmalen; Rolf Kanninga; Mohamed El Khattabi; Jolanda Neef; Sandrine Audouy; Tjibbe Bosma; Anneke Kuipers; Eduard Post; Anton Steen; Jan Kok; Girbe Buist; Oscar P. Kuipers; George T. Robillard; Kees Leenhouts
Vaccine | 2007
Sandrine Audouy; Saskia van Selm; Maarten L. van Roosmalen; Eduard Post; Rolf Kanninga; Jolanda Neef; Silvia Estevão; Edward E. S. Nieuwenhuis; Peter V. Adrian; Kees Leenhouts; Peter W. M. Hermans
Vaccine | 2006
Sandrine Audouy; Maarten L. van Roosmalen; Jolanda Neef; Rolf Kanninga; Eduard Post; Mariëlle van Deemter; Heidi Metselaar; Saskia van Selm; George T. Robillard; Kees Leenhouts; Peter W. M. Hermans
10th Meeting of the NATO-Advanced-Studies-Institute on Targeting of Drugs: Strategies for Gene Constructs and Delivery | 2000
Volker Oberle; Inge S. Zuhorn; Sandrine Audouy; Udo Bakowsky; J. Smisterova; Jan B. F. N. Engberts; Dick Hoekstra